BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24567410)

  • 1. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
    Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism.
    Iwata TN; Ramírez JA; Tsang M; Park H; Margineantu DH; Hockenbery DM; Iritani BM
    J Immunol; 2016 Sep; 197(6):2250-60. PubMed ID: 27521345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin-Resistant mTOR Activity Is Required for Sensory Axon Regeneration Induced by a Conditioning Lesion.
    Chen W; Lu N; Ding Y; Wang Y; Chan LT; Wang X; Gao X; Jiang S; Liu K
    eNeuro; 2016; 3(6):. PubMed ID: 28101526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors.
    Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT
    Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.
    Hua C; Guo H; Bu J; Zhou M; Cheng H; He F; Wang J; Wang X; Zhang Y; Wang Q; Zhou J; Cheng T; Xu M; Yuan W
    Exp Hematol; 2014 Dec; 42(12):1031-40.e1-4. PubMed ID: 25201756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L; Houghton PJ
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis.
    Hoshii T; Matsuda S; Hirao A
    J Biochem; 2014 Aug; 156(2):73-83. PubMed ID: 24962700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
    Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
    Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.
    Kalaitzidis D; Sykes SM; Wang Z; Punt N; Tang Y; Ragu C; Sinha AU; Lane SW; Souza AL; Clish CB; Anastasiou D; Gilliland DG; Scadden DT; Guertin DA; Armstrong SA
    Cell Stem Cell; 2012 Sep; 11(3):429-39. PubMed ID: 22958934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of rictor as a novel substrate of Polo-like kinase 1.
    Shao T; Liu X
    Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.